Outcomes of catheter ablation in high-risk patients with Brugada syndrome refusing an implantable cardioverter defibrillator implantation
Europace · 2023
DOI: 10.1093/europace/euad318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2023. Verfasst von Le Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chinese Academy of Medical Sciences, Peking Union Medical College, National Center for Cardiovascular Diseases, Fuwai Hospital, Beilishi Road 167#, X…. Hauptthemen laut MEDLINE: Brugada Syndrome, Defibrillators, Implantable, Catheter Ablation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical and Health Technology Innovation Project of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Aims
The aim of this study was to investigate the outcomes of catheter ablation (CA) in preventing arrhythmic events among patients with symptomatic Brugada syndrome (BrS) who declined implantable cardioverter defibrillator (ICD) implantation. Methods and results A total of 40 patients with symptomatic BrS were included in the study, of which 18 refused ICD implantation and underwent CA, while 22 patients received ICD implantation. The study employed substrate modification (including endocardial and epicardial approaches) and ventricular fibrillation (VF)-triggering pre-mature ventricular contraction (PVC) ablation strategies. The primary outcomes were a composite endpoint consisting of episodes of VF and sudden cardiac death during the follow-up period. The study population had a mean age of 43.8 ± 9.6 years, with 36 (90.0%) of them being male. All patients exhibited the typical Type 1 BrS electrocardiogram pattern, and 16 (40.0%) were carriers of an SCN5A mutation. The Shanghai risk scores were comparable between the CA and the ICD groups (7.05 ± 0.80 vs. 6.71 ± 0.86, P = 0.351). Ventricular fibrillation–triggering PVCs were ablated in 3 patients (16.7%), while VF substrates were ablated in 15 patients (83.3%). Epicardial ablation was performed in 12 patients (66.7%). During a median follow-up of 46.2 (17.5–73.7) months, the primary outcomes occurred more frequently in the ICD group than in the CA group (5.6 vs. 54.5%, Log-rank P = 0.012).
Conclusion
Catheter ablation is an effective alternative therapy for improving arrhythmic outcomes in patients with symptomatic BrS who decline ICD implantation. Our findings support the consideration of CA as an alternative treatment option in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chinese Academy of Medical Sciences, Peking Union Medical College, National Center for Cardiovascular Diseases, Fuwai Hospital, Beilishi Road 167#, Xicheng District, Beijing 100037, China.
ORCID-Profile: Le Li, Lihui Zheng, Zhenhao Zhang, Yulong Xiong, Zhuxin Zhang, Yan Yao
Förderung
- Medical and Health Technology Innovation Project of Chinese Academy of Medical Sciences
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Zitieren
APA
Li, L., Ding, L., Zhou, L., Wu, L., Zheng, L., Zhang, Z., Xiong, Y., Zhang, Z., & Yao, Y. (2023). Outcomes of catheter ablation in high-risk patients with Brugada syndrome refusing an implantable cardioverter defibrillator implantation. Europace. https://doi.org/10.1093/europace/euad318
Vancouver
Li L, Ding L, Zhou L, Wu L, Zheng L, Zhang Z, et al. Outcomes of catheter ablation in high-risk patients with Brugada syndrome refusing an implantable cardioverter defibrillator implantation. Europace. 2023. doi:10.1093/europace/euad318
BibTeX
@article{Li2023,
author = {Li, Le and Ding, Ligang and Zhou, Likun and Wu, Lingmin and Zheng, Lihui and Zhang, Zhenhao and Xiong, Yulong and Zhang, Zhuxin and Yao, Yan},
title = {Outcomes of catheter ablation in high-risk patients with Brugada syndrome refusing an implantable cardioverter defibrillator implantation},
journal = {Europace},
year = {2023},
doi = {10.1093/europace/euad318}
}
EUVIMED